Valuation: Apogee Therapeutics, Inc.

Market Cap 9.93B 8.71B 8.03B 7.52B 14.1B 937B 14.39B 96.5B 37.34B 463B 37.3B 36.49B 1,606B P/E 2026 *
-30.7x
P/E 2027 * -23.7x
Enterprise Value 8.95B 7.85B 7.24B 6.78B 12.71B 845B 12.97B 86.99B 33.66B 417B 33.63B 32.89B 1,448B EV / Sales 2026 *
985x
EV / Sales 2027 * 736x
Free-Float
87.2%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day-0.10%
1 week+46.66%
Current month+61.37%
1 month+60.07%
3 months+69.03%
6 months+71.43%
Current year+75.61%
1 week 132.45
Extreme 132.45
133.16
1 month 77
Extreme 77
133.16
Current year 60.35
Extreme 60.35
133.16
1 year 34.34
Extreme 34.34
133.16
3 years 14.19
Extreme 14.19
133.16
5 years 14.19
Extreme 14.19
133.16
10 years 14.19
Extreme 14.19
133.16
Manager TitleAgeSince
Chief Executive Officer 36 01/09/2022
Director of Finance/CFO 60 01/01/2023
Chief Tech/Sci/R&D Officer - 01/05/2023
Director TitleAgeSince
Director/Board Member 54 22/06/2023
Director/Board Member 62 01/06/2023
Director/Board Member 36 01/06/2023
Date Insider Type Main position Quantity % Market Cap.
06-22Sell

Chief Technology Officer

-26,400 0.0471%
06-22Sell

Chief Executive Officer

-80,000 0.1429%
06-10Sell

Chief Executive Officer

-20,000 0.0357%
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%+46.66%+202.56% - 9.93B
-0.48%+7.20%-5.08%+2.45% 46.2B
+2.19%+11.71%+385.81%+632.13% 38.71B
+2.53%+13.93%+20.85%-10.61% 31.9B
+1.65%+3.61%+9.98%+55.42% 31.12B
-4.16%-2.58%+8.74%+15.22% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+71.80%+134.14% 15.05B
+1.00%+10.30%+13.31%+22.84% 13.74B
+3.63%+9.53%+104.07%+107.62% 13.42B
Average +0.73%+12.89%+90.23%+119.90% 24B
Weighted average by Cap. +0.72%+10.28%+91.83%+140.75%

Financials

2026 *2027 *
Net sales 9.09M 7.97M 7.35M 6.88M 12.9M 858M 13.17M 88.31M 34.17M 424M 34.14M 33.39M 1.47B 12.5M 10.96M 10.1M 9.46M 17.74M 1.18B 18.1M 121M 46.98M 583M 46.94M 45.91M 2.02B
Net income -318M -278M -257M -240M -451M -29.95B -460M -3.08B -1.19B -14.8B -1.19B -1.17B -51.33B -416M -365M -337M -315M -591M -39.28B -603M -4.05B -1.57B -19.42B -1.56B -1.53B -67.32B
Net Debt -980M -859M -792M -741M -1.39B -92.4B -1.42B -9.51B -3.68B -45.67B -3.68B -3.6B -158B -740M -649M -598M -560M -1.05B -69.83B -1.07B -7.19B -2.78B -34.51B -2.78B -2.72B -120B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
26/06/26 $132.55 -0.10% 5,109,502
25/06/26 $132.68 -0.01% 4,952,655
24/06/26 $132.69 -0.14% 7,739,644
23/06/26 $132.88 +0.25% 11,320,483
22/06/26 $132.55 +46.66% 61,663,544
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
132.55USD
Average target price
130.53USD
Spread / Average Target
-1.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock